High affinity human Fc specific monoclonal antibodies for capture kinetic analyses of antibody-antigen interactions.

Anti-human Fc Capture kinetics Immunoassay Label-free optical biosensor Monoclonal antibody

Journal

Analytical biochemistry
ISSN: 1096-0309
Titre abrégé: Anal Biochem
Pays: United States
ID NLM: 0370535

Informations de publication

Date de publication:
01 03 2022
Historique:
received: 12 08 2021
revised: 05 11 2021
accepted: 08 11 2021
pubmed: 18 11 2021
medline: 11 2 2022
entrez: 17 11 2021
Statut: ppublish

Résumé

We recently demonstrated that capturing human monoclonal antibodies (hmAbs) using high affinity anti-human Fc (AHC) antibodies allows reliable characterization of antibody-antigen interactions. Here, we characterized six human Fc specific mouse monoclonal antibodies (mAbs) and compared their binding profiles with three previously characterized goat AHC polyclonal antibodies (pAbs), exhibiting properties of a good capture reagent. All six mouse AHC mAbs specifically bound with high affinity to the Fc region of hIgG1, hIgG2, hIgG4 and to 43 different hIgG variants, containing substitutions and/or mutations in the hinge and/or Fc region, that have been reported to exhibit modified antibody effector function and/or pharmacokinetics. Biacore sensor surfaces individually derivatized with mouse AHC mAbs exhibited >2.5-fold higher hIgG binding capacity compared to the three goat AHC pAb surfaces and reproducibly captured hIgG over 300 capture-regeneration cycles. The results of the capture kinetic analyses performed on 31 antibody-antigen interactions using surfaces derivatized with either of the two highest affinity AHC mAbs (REGN7942 or REGN7943) were in concordance with those performed using goat AHC pAb surfaces. Our data demonstrate that AHC mAbs such as REGN7942 and REGN7943 that have properties superior than the three goat AHC pAbs are highly valuable research reagents, especially to perform capture kinetic analyses of antibody-antigen interactions on optical biosensors.

Identifiants

pubmed: 34788604
pii: S0003-2697(21)00356-0
doi: 10.1016/j.ab.2021.114455
pii:
doi:

Substances chimiques

Antibodies, Monoclonal 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

114455

Informations de copyright

Copyright © 2021 Regeneron Pharmaceuticals. Published by Elsevier Inc. All rights reserved.

Auteurs

Vishal Kamat (V)

Therapeutic Proteins, Regeneron Pharmaceuticals, USA. Electronic address: vishal.kamat@regeneron.com.

Candice Boutot (C)

Therapeutic Proteins, Regeneron Pharmaceuticals, USA.

Ashique Rafique (A)

Therapeutic Proteins, Regeneron Pharmaceuticals, USA.

Christian Granados (C)

Therapeutic Proteins, Regeneron Pharmaceuticals, USA.

Jing Wang (J)

Therapeutic Proteins, Regeneron Pharmaceuticals, USA.

Ashok Badithe (A)

Therapeutic Proteins, Regeneron Pharmaceuticals, USA.

Marcela Torres (M)

Therapeutic Proteins, Regeneron Pharmaceuticals, USA.

Ishita Chatterjee (I)

Therapeutic Proteins, Regeneron Pharmaceuticals, USA.

Olav Olsen (O)

Therapeutic Proteins, Regeneron Pharmaceuticals, USA.

William Olson (W)

Therapeutic Proteins, Regeneron Pharmaceuticals, USA.

Tammy Huang (T)

Therapeutic Proteins, Regeneron Pharmaceuticals, USA.

Articles similaires

Humans Amyotrophic Lateral Sclerosis Male Middle Aged Female
Humans Epitopes Antibodies, Monoclonal Immunoglobulin Fab Fragments Cryoelectron Microscopy

Antigen targeting and anti-tumor activity of a novel anti-CD146

Kim Lindland, Marion Masitsa Malenge, Ruth Gong Li et al.
1.00
Animals Humans CD146 Antigen Mice Immunoconjugates
1.00
Animals Hematopoietic Stem Cells Mice, SCID Mice Hematopoietic Stem Cell Transplantation

Classifications MeSH